Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
Under the EU Clinical Trials Regulation, financial incentives are not allowed for participants under 16 to prevent undue ...
Moderna ( NASDAQ: MRNA) shares snapped six straight sessions of losses, as the stock closed 0.46% higher at $63.93 on ...
Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...
Shares of Moderna Inc. MRNA inched 0.46% higher to $63.93 Thursday, on what proved to be an all-around positive trading ...
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...
Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...
Shares of Moderna Inc. MRNA dropped 0.31% to $63.94 Tuesday, on what proved to be an all-around favorable trading session for ...
Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...
GSK's decision not to advance the vaccine into Phase III trials ends its ambition to bring the first HSV vaccine to market.